Meningococcal meningitis is a rare but potentially devastating disease which can strike anyone, anywhere in the world. 1
Fortunately, most cases can be prevented through vaccination. 1,3
At Sanofi, we believe in a world where no one should suffer or die from this vaccine preventable disease. 1,2
Meningococcal meningitis mainly affects children under five, adolescents and young adults, but it can happen to anyone at any age1,3
This disease may lead to long-term complications and even death in less than 24 hours1
There are different types of the bacteria that can cause meningococcal meningitis, but vaccines exist for 5 of the most common types1,3
The need to better understand meningococcal meningitis
Davide, athlete and meningococcal meningitis survivor
Joining forces against acute bacterial meningitis
For over 45 years, Sanofi has been at the forefront of combating meningococcal epidemics and in driving meningococcal vaccine evolution
The fight against meningococcal meningitis is in our hands
- WHO. Meningococcal meningitis. Available at: https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis Accessed February 2021.
- ECDC. Factsheet about meningococcal disease. Available at: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet Accessed February 2021.
- Meningitis Research Foundation. What are meningitis and septicaemia. Available at: https://www.meningitis.org/meningitis/what-is-meningitis Accessed February 2021.
- Sanofi Pasteur (2020). Meningococcal Disease in Europe: A Rare but Devastating Disease.
MAT-GLB-2100961 v3 - 04/2022